Extending the Horizon for Cell-Based Immunotherapy by Understanding the Mechanisms of Action of Photopheresis

Transfusion Medicine Reviews

Volumn 24, Issue 1, 2010, Pages 22-32

  Voss, Ching Y ^a,b   Fry, Terry J ^a,b   Coppes, Max J ^a,b   Blajchman, Morris A ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BLOOD TRANSFUSION; CELL FUNCTION; CELL INTERACTION; CELL THERAPY; CLINICAL TRIAL; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NONHUMAN; PUVA; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION;

ANTIGEN-PRESENTING CELLS; APOPTOSIS; AUTOANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LEUKOCYTES; PHOTOPHERESIS;

EID: 70749129348     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2009.09.008     Document Type: Article

References (99)

1. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12 (2006) 7-12
2. Marshall S.R. Technology insight: ECP for the treatment of GvHD-Can we offer selective immune control without generalized immunosuppression?. Nat Clin Pract Oncol 3 (2006) 302-314
3. Seaton E.D., Szydlo R.M., Kanfer E., et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 102 (2003) 1217-1223
4. Greinix H.T., Sociė G., Bacigalupo A., et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 38 (2006) 265-273
5. Abreu M.T., Von Tirpitz C., Hardi R., et al. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study. Inflamm Bowel Dis 15 (2009) 829-836
6. Vamvakas E.C., and Blajchman M.A. Transfusion-related immunomodulation (TRIM): An update. Blood Rev 21 (2007) 327-348
7. Silvis R., Steup W.H., Brand A., et al. Protective effect of blood transfusions on postoperative recurrence of Crohn's disease in parous women. Transfusion 34 (1994) 242-247
8. Albert M.L. Death-defying immunity: Do apoptotic cells influence antigen processing and presentation?. Nat Rev Immunol 4 (2004) 223-231
9. Scheller C., Knöferle J., Ullrich A., et al. Caspase inhibition in apoptotic T cells triggers necrotic cell death depending on the cell type and the proapoptotic stimulus. J Cell Biochem 97 (2005) 1350-1361
10. Gavathiotis E., Suzuki M., Davis M.L., et al. BAX activation is initiated at a novel interaction site. Nature 455 (2008) 1076-1081
11. Griffith T.S., Kazama H., VanOosten R.L., et al. Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL. J Immunol 178 (2007) 2679-2687
12. + T cells. Nat Immunol 9 (2008) 122-123
13. Hettmer S., Malott C., Woods W., et al. Biological stratification of human neuroblastoma by complex "B" pathway ganglioside expression. Cancer Res 63 (2003) 7270-7276
14. Caldwell S., Heitger A., Shen W., et al. Mechanisms of ganglioside inhibition of APC function. J Immunol 171 (2003) 1676-1683
15. McKallip R., Li R., and Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 163 (1999) 3718-3726
16. David R. Regulatory T cells: Suppression dissected. Nat Rev Immunol 9 (2009) 150-151
17. Fink S.L., and Cookson B.T. Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells. Infect Immun 73 (2005) 1907-1916
18. Akbari O., Freeman G.J., Meyer E.H., et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 8 (2002) 1024-1032
19. Bell E. Tolerance: Key role for DCs in preventing autoimmunity. Nat Rev Immunol 9 (2009) 224-225
20. Van Rhijn I., Young D.C., De Jong A., et al. CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acids. J Exp Med 206 (2009) 1409-1422
21. Chen X., Wang X., Keaton J.M., et al. Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules. J Immunol 178 (2007) 6181-6190
22. Moody D.B., Zajonc D.M., and Wilson I.A. Anatomy of CD1-lipid antigen complexes. Nat Rev Immunol 5 (2005) 387-399
23. Silva M.T., do Vale A., and dos Santos N.M. Secondary necrosis in multicellular animals: An outcome of apoptosis with pathogenic implications. Apoptosis 113 (2008) 463-482
24. Ohnmacht C., Pullner A., King S.B., et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cell and results in spontaneous fatal autoimmunity. J Exp Med 206 (2009) 549-559
25. Von Boehmer H., and Nolting J. What turns on Foxp3?. Nat Immunol 9 (2008) 121-122
26. Tone Y., Furuuchi K., Kojima Y., et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 9 (2008) 194-202
27. Gaipl U.S., Beyer T.D., Baumann I., et al. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal-Implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology 207 (2003) 73-81
28. Munoz L.E., Gaipl U.S., Franz S., et al. SLE-A disease of clearance deficiency?. Rheumatology 44 (2005) 1101-1107
29. Dumitriu I.E., Baruah P., Valentinis B., et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174 (2005) 7506-7515
30. Khor B., and Makar R.S. Toward a molecular explanation for cross-presentation of antigens to the immune system. Transfus Med Rev 22 (2008) 188-201
31. Blachėre N.E., Darnell R.B., and Albert M.L. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PloS Biol 3 (2005) e185
32. Kurts C., Sutherland R.M., Davey G., et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci USA 96 (1999) 12703-12707
33. Kurts C., Health W.R., Kosaka H., et al. The peripheral deletion of autoreactive CD8 T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med 188 (1998) 415-420
34. Yamazaki S., Dudziak D., Heidkamp G.F., et al. CD8+CD205+ splenic dendritic cells are specialized to induce FOXP3+ regulatory T cells. J Immunol 181 (2008) 6923-6933
35. Bird L. T cell responses: Directing responses in death. Nat Rev Immunol 9 (2009) 222
36. H17 cell differentiation. Nature 458 (2009) 78-82
37. Stockinger B. Cause of death matters. Nature 458 (2009) 44-45
38. Kanai K., and Watanabe M. Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 5 (2005) 451-462
39. Lathrop S.K., Santacruz N.A., Pham D., et al. Antigen-specific peripheral shaping of the natural regulatory T cell population. J Exp Med 205 (2008) 3105-3117
40. Klinger M., Kim J.K., Chmura S.A., et al. Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands. J Immunol 182 (2009) 4581-4589
41. Jiang H., and Chess L. Qa-1/HLA-E restricted regulatory CD8+ T cells and self-nonself discrimination: An essay on peripheral T-cell regulation. Hum Immunol 69 (2008) 721-727
42. Gilliet M., and Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195 (2002) 695-704
43. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome(IPEX) is caused by mutations of FOXP3. Nat Genet 27 (2001) 20-21
44. H2 responses. Nature 458 (2009) 351-356
45. Sgouroudis E., and Piccirillo C.A. Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: Lessons from mouse models and implications for human disease. Diabetes Metab Res Rev 25 (2009) 208-218
46. Kuhn A., Beissert S., and Krammer P.H. CD4(+) CD25 (+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res 301 (2009) 71-81
47. +, in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol 156 (2009) 320-327
48. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
49. Rong G., Zhou Y., Xiong Y., et al. Imbalance between T helper Type 17 and T regulatory cells in patients with primary biliary cirrhosis: The serum cytokine profile and peripheral cell population. Clin Exp Immunol 156 (2009) 217-225
50. Chen C.C., and Manning A.M. TGF-β1, IL-10 and IL-4 differentially modulate the cytokine-induced expression of IL-6 and IL-8 in human endothelial cells. Cytokine 8 (1996) 58-65
51. Ashwood P., Harvey R., Verjee T., et al. Functional interactions between mucosal IL-1, IL-ra and TGF-beta1 in ulcerative colitis. Inflamm Res 53 (2004) 53-59
52. Gomez G., Ramirez C., Rivera J., et al. TGF-β1 inhibits mast cell Fce{open}R1 expression. J Immunol 174 (2005) 5987-5993
53. Brivio F., Fumagalli L., Parolini D., et al. T-helper/T-regulator lymphocyte ratio as a new immunobiological index to quantify the anticancer immune status in cancer patients. In Vivo 22 (2008) 647-650
54. Editorial: Essence of harmony. Nat Immunol 6 (2005) 325
55. Pincus M.R., and Abraham N.Z. Interpreting laboratory results. In: Henry J.B. (Ed). Clinical Diagnosis and Management by Laboratory Methods. Ed 12 (2001), W.B. Saunders, Philadelphia 92-107
56. Edelson R.L. Photopheresis: A new therapeutic concept. Yale J Biol Med 62 (1989) 565-577
57. Maeda A., Schwarz A., Kernebeck K., et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 174 (2005) 5968-5976
58. Legitimo A., Consolini R., Di Stefano R., et al. Psoralen and UVA light: An in vitro investigation of multiple immunological mechanisms underlying the immunosuppression induction in allograft rejection. Blood Cells Mol Dis 29 (2002) 24-34
59. Lamioni A., Parisi F., Isacchi G., et al. The immunological effects of extracorporeal photopheresis unraveled: Induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 79 (2006) 846-850
60. Savill J., Dransfield I., Gregory C., et al. A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2 (2002) 965-975
61. Morelli A.E., Larregina A.T., Shufesky W.J., et al. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: Dependence on complement receptors and effect on cytokine production. Blood 101 (2003) 611-620
62. Mahnke K., Knop J., and Enk A.H. Induction of tolerogenic DCs: "You are what you eat". Trends Immunol 24 (2003) 646-651
63. Steinman R.M., Turley S., Mellman I., et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191 (2000) 411-416
64. Gerner M., Hölig K., Wehner R., et al. Extracorporeal photopheresis efficiently impairs the proinflammatroy capacity of human 6-sulfo Lac NAc dendritic cells. Transplantation 87 (2009) 1134-1139
65. Maeda A., Schwarz A., Bullinger A., et al. Experimental extracorporeal photopheresis inhibits the sensitization and effector phases of contact hypersensitivity via two mechanisms: Generation of IL-10 and induction of regulatory T cells. J Immunol 181 (2008) 5956-5962
66. Gatza E., Rogers C.E., Clouthier S.G., et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 112 (2008) 1515-1521
67. Lamioni A., Carsetti R., Legato A., et al. Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation 83 (2007) 1393-1396
68. Kanold J., Merlin E., Halle P., et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: Clinical practice guidelines based on field experience and review of the literature. Transfusion 47 (2009) 2276-2289
69. Couriel D., Hosing C., Saliba R., et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: Does it work?. Biol Blood Marrow Transplant 12 (2009) 37-40
70. Messina C., Locatelli F., lanino E., et al. Extracorporeal photochemotherapy for paediatric patients post stem cell transplantation. Br J Haematol 122 (2003) 118-127
71. O'Hagan A.R., Stillwell P.C., Arroliga A., et al. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 115 (1999) 1459-1462
72. Barr M.L., Melser B.M., Elsen H.J., et al. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med 339 (1998) 1744-1751
73. Foss F.M., Gorgun G., and Miller K.B. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant 29 (2002) 719-725
74. Opelz G., Sengar D.P.S., Mickey M.R., et al. Effect of blood transfusion on subsequent kidney transplants. Transplant Proc 5 (1973) 253-259
75. Landers D.F., Hill G.E., Wong K.C., et al. Blood transfusion-induced immunomodulation. Anesth Analg 82 (1996) 187-204
76. Peters W.R., Fry R.D., Fleshman J.W., et al. Multiple blood transfusions reduce the recurrence rate of Crohn's disease. Dis Colon Rectum 32 (1989) 749-753
77. Williams J.G., and Hughes L.E. Effect of perioperative blood transfusion on recurrence of Crohn's disease. Lancet 2 (1989) 131-133
78. Mowbray J.F., Gibbings C., Liddell H., et al. Controlled trial of treatment of recurrent spontaneous abortion by immunization with paternal cells. Lancet 1 (1985) 941-943
79. Dzik W.H., and Szczepiorkowski Z.M. Leukocyte reduced products. In: Hillyer C.D., Silberstein L.E., Ness P.M., and Anderson K.C. (Eds). Blood Banking and Transfusion Medicine Basic Principles & Practice. 1st ed (2003), Churchill Livingstone, Philadelphia 219-220
80. Womer K.L., and Sayegh M.H. Donor antigen and transplant tolerance strategies: It takes two to tango!. J Am Soc Nephrol 15 (2004) 1101-1103
81. Persijn G.G., Cohen B., Lansbergen Q., et al. Retrospective and prospective studies on the effect of blood transfusions in renal transplantation in the Netherlands. Transplantation 28 (1979) 396-401
82. Blajchman M.A., Bardossy L., Carmen R., et al. Allogeneic blood-transfusion-induced enhancement of tumor growth: Two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 81 (1993) 1880-1892
83. Bordin J., Bardossy L., and Blajchman M.A. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: The importance of timing of leukodepletion. Blood 84 (1994) 344-348
84. Thomson A.W., Lu L., Murase N., et al. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells 13 (1995) 622-639
85. Clark D.A., Gorczynski R.M., and Blajchman M.A. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen. Transfusion 48 (2008) 814-821
86. Blajchman M.A., and Bordin J.O. Mechanisms of transfusion-associated immunosuppression. Curr Opin Hematol 1 (1994) 457-461
87. Hébert P.C., Fergusson D., Blajchman M.A., et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 289 (2003) 1941-1949
88. Borel J.F., and Kis Z.L. The discovery and development of cyclosporine. Transplant Proc 23 (1991) 1867-1874
89. Blajchman M.A. Transfusion immunomodulation or TRIM: What does it mean clinically?. Hematology 10 Suppl 1 (2005) 208-214
90. Opelz G., Vanrenterghem Y., Kirste G., et al. prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 63 (1997) 964-967
91. Brunson M.E., and Alexander J.W. Mechanisms of transfusion-induced immunosuppression. Transfusion 30 (1990) 651-658
92. Klein L., Khazaie K., and Von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA 100 (2003) 8886-8891
93. Waanders M.M., Roelen D.L., Brand A., et al. The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response. Transfus Med Rev 19 (2005) 281-287
94. Claas F.H., de Koster H.S., Lagaaij E.L., et al. A molecular mechanism of T cell downregulation by blood transfusion. Exp Nephrol 1 (1993) 134-138
95. Roelen D.L., van Bree S., van Hulst P., et al. Regulatory functions of human CD4(+) T cells recognizing allopeptides in the context of self-HLA class II. Hum Immunol 63 (2002) 902-911
96. Roelen D., Brand A., and Claas F.H. Pretransplant blood transfusions revisited: A role for CD(4+) regulatory T cells?. Transplantation 77 (2004) S26-S28
97. Böhm M., Luger T.A., Schneider M., et al. New insight into immunosuppression and treatment of autoimmune diseases. Clin Exp Rheumatol 24 suppl. 40 (2006) S67-S71
98. Noris M., Casiraghi F., Todeschini M., et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 18 (2007) 1007-1018
99. Guerin L.R., Prins J.R., and Robertson S.A. Regulatory T cells and immune tolerance in pregnancy: A new target for infertility treatment?. Hum Reprod Update 15 (2009) 517-535